Pharmacyclics’ Leukemia Drug Beats Glaxo’s in Head-to-Head TrialBusinessweekPharmacyclics Inc. (PCYC:US)’s Imbruvica, introduced this year for chronic lymphocytic leukemia, helped patients live longer without their disease worsening than GlaxoSmithKline Plc’s treatment for the blood cancer. In a head-to-head comparison, 391 …IMBRUVICA® (ibrutinib) Shows Durable, Long-Term Responses for Patients …NEWS.GNOM.ESNew Pill Helps Leukemia Patients Live LongerNBCNews.comIMBRUVICA® (ibrutinib) Significantly Improves Progression Free Survival …MarketWatchReuters UKall 13 news articles …Read Full Story
Pharmacyclics' Leukemia Drug Beats Glaxo's in Head-to-Head Trial - Businessweek
Real Estate of Cebu
